Mary Cianfrocca

1.9k total citations
31 papers, 1.3k citations indexed

About

Mary Cianfrocca is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Mary Cianfrocca has authored 31 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Cancer Research and 8 papers in Genetics. Recurrent topics in Mary Cianfrocca's work include Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Treatment and Pharmacology (9 papers). Mary Cianfrocca is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Treatment and Pharmacology (9 papers). Mary Cianfrocca collaborates with scholars based in United States, Canada and Philippines. Mary Cianfrocca's co-authors include Lori J. Goldstein, Edgardo Rivera, Bruce J. Dezube, Susan E. Krown, Jeannette Y. Lee, Jamie Von Roenn, William J. Gradishar, Charles Lee, David M. Aboulafia and Joseph A. Sparano and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Mary Cianfrocca

31 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Cianfrocca United States 14 869 533 279 239 232 31 1.3k
Henry G. Kaplan United States 22 831 1.0× 396 0.7× 337 1.2× 325 1.4× 233 1.0× 79 1.6k
Gian Luigi Cetto Italy 19 666 0.8× 369 0.7× 199 0.7× 183 0.8× 290 1.3× 59 1.1k
Laura Pizzuti Italy 23 906 1.0× 410 0.8× 140 0.5× 333 1.4× 454 2.0× 96 1.7k
P. Hupperets Netherlands 21 629 0.7× 340 0.6× 165 0.6× 266 1.1× 328 1.4× 40 1.4k
Daniel Vorobiof South Africa 18 938 1.1× 300 0.6× 340 1.2× 390 1.6× 153 0.7× 61 1.6k
Robert P. Gray United States 15 718 0.8× 859 1.6× 352 1.3× 181 0.8× 197 0.8× 26 1.3k
Aafke H. Honkoop Netherlands 17 1.1k 1.3× 495 0.9× 207 0.7× 364 1.5× 189 0.8× 33 1.5k
Mireia Margelí Vila Spain 20 784 0.9× 485 0.9× 127 0.5× 416 1.7× 440 1.9× 94 1.4k
Ellen Schlichting Norway 21 834 1.0× 676 1.3× 224 0.8× 213 0.9× 420 1.8× 44 1.6k
H. Curé France 22 1.2k 1.4× 742 1.4× 410 1.5× 327 1.4× 183 0.8× 82 2.0k

Countries citing papers authored by Mary Cianfrocca

Since Specialization
Citations

This map shows the geographic impact of Mary Cianfrocca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Cianfrocca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Cianfrocca more than expected).

Fields of papers citing papers by Mary Cianfrocca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Cianfrocca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Cianfrocca. The network helps show where Mary Cianfrocca may publish in the future.

Co-authorship network of co-authors of Mary Cianfrocca

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Cianfrocca. A scholar is included among the top collaborators of Mary Cianfrocca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Cianfrocca. Mary Cianfrocca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salgia, Nicholas, Alex Chehrazi‐Raffle, Joann Hsu, et al.. (2021). Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine. 10(16). 5671–5680. 2 indexed citations
2.
Mortimer, Joanne, Laura Kruper, Mary Cianfrocca, et al.. (2020). Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care. Journal of Clinical Medicine. 9(6). 1984–1984. 3 indexed citations
3.
Liu, Jennifer, Simran Padam, Daneng Li, et al.. (2020). Strategies to Improve Participation of Older Adults in Cancer Research. Journal of Clinical Medicine. 9(5). 1571–1571. 17 indexed citations
4.
5.
Margolese, Richard G., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet. 387(10021). 849–856. 127 indexed citations
6.
Rivera, Edgardo & Mary Cianfrocca. (2015). Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 75(4). 659–670. 120 indexed citations
7.
Margolese, Richard G., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. Journal of Clinical Oncology. 33(15_suppl). LBA500–LBA500. 1 indexed citations
8.
Kumthekar, Priya, Sean Grimm, Michael J. Avram, et al.. (2013). Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. Journal of Neuro-Oncology. 112(2). 247–255. 47 indexed citations
9.
Cianfrocca, Mary, Virginia Kaklamani, Steven T. Rosen, et al.. (2012). Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results.. Journal of Clinical Oncology. 30(15_suppl). 610–610. 1 indexed citations
10.
Kaklamani, Virginia, Kalliopi P. Siziopikou, Denise Scholtens, et al.. (2011). Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Research and Treatment. 132(3). 833–842. 27 indexed citations
11.
12.
Cianfrocca, Mary, Charles Lee, Jamie Von Roenn, et al.. (2010). Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma. Cancer. 116(16). 3969–3977. 109 indexed citations
13.
Cianfrocca, Mary. (2008). Application of epothilones in breast cancer therapy. Current Opinion in Oncology. 20(6). 634–638. 7 indexed citations
14.
Cianfrocca, Mary. (2008). Overcoming Recurrence Risk: Extended Adjuvant Endocrine Therapy. Clinical Breast Cancer. 8(6). 493–500. 12 indexed citations
15.
Cianfrocca, Mary, Sarah J.L. Flatters, Gary J. Bennett, et al.. (2006). Peripheral Neuropathy in a Woman With Breast Cancer. Journal of Pain. 7(1). 2–10. 7 indexed citations
16.
Cianfrocca, Mary & Lori J. Goldstein. (2004). Prognostic and Predictive Factors in Early-Stage Breast Cancer. The Oncologist. 9(6). 606–616. 469 indexed citations
17.
Freedman, Gary M., Penny R. Anderson, Lori J. Goldstein, et al.. (2003). Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older. Cancer. 98(5). 918–925. 36 indexed citations
18.
Cianfrocca, Mary, Timothy P. Cooley, Jeannette Y. Lee, et al.. (2002). Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi’s Sarcoma: A Phase I AIDS Malignancy Consortium Study. Journal of Clinical Oncology. 20(1). 153–159. 42 indexed citations
19.
Cianfrocca, Mary & Lori J. Goldstein. (2001). Operable breast cancer. Current Treatment Options in Oncology. 2(2). 157–167. 3 indexed citations
20.
Cianfrocca, Mary & Jamie H. Von Roenn. (1997). Wasting and Cachexia in Patients with HIV. AIDS Patient Care and STDs. 11(4). 259–267. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Henry G. Kaplan Breakdown of academic impact, for papers by Gian Luigi Cetto Breakdown of academic impact, for papers by Laura Pizzuti Breakdown of academic impact, for papers by P. Hupperets Breakdown of academic impact, for papers by Daniel Vorobiof Breakdown of academic impact, for papers by Robert P. Gray Breakdown of academic impact, for papers by Aafke H. Honkoop Breakdown of academic impact, for papers by Mireia Margelí Vila Breakdown of academic impact, for papers by Ellen Schlichting Breakdown of academic impact, for papers by H. Curé
Rankless by CCL
2026